



Canada Health Infoway

Public Health Surveillance (PHS) Community

Agenda and Notes

September 5, 2024, 2:00–3:00 pm ET

PHS Community Agenda

1. Welcome and Introductions (5 min)
2. New Covid-19 vaccines (Nicolas Gilbert & Naureen Mukhi) (10 min)
3. CIHI Value sets supporting pCHDCF (Jacqueline Singer) (15 min)
4. New Requests Since Last Meeting And August Release Of The SNOMED CT CA Edition (5 min)
5. Follow-up on The Picklist (clinician/public) Terms (10 min)
6. Follow-up on Who Uses The Antigen And Immunoglobulin Joint Subset And The Objective? (5 min)
7. Merging Options For The Tradename And Generic/Historical Subsets (5 min)
8. Prioritization Of Work Items (2 min)
9. Questions/Wrap Up (3 min)

PHS Community Notes - New Covid-19 Vaccines

1. Upon Nicolas' request an 'out-of-cycle' meeting is required before the October monthly meeting, to discuss the options the PHSC would like to apply to the new coming COVID-19 vaccines
2. ACTION:
 1. Linda to schedule a call the week of September 9
 2. Linda to draft the details of the proposal and potential options

PHS Community Notes - CIHI Value Sets Supporting pCHDCF

1. Please review the slides 10: Immunization Reason Value Set and 11: Identifying immunocompromised individuals.
2. ACTION:
 1. Provide your comments and feedback as soon as possible, at: connectedcare@cihi.ca

PHS Community Notes – Prioritization Of Working Items

1. The PHSC is invited to share what they see as higher to lower priority for the following known items that will require work from both the PHSC and Infoway

1. Patient-Friendly Picklist
2. Enhanced Clinician Picklist (Preferred Terms review)
3. Antigen/Immunglobulin content modification
4. Subset mergings
5. Potential new NVC subsets ?

2. ACTION:

1. Bring this topic at the next PHSC meeting.
2. Discuss the impact of each work area, the dependencies and the timelines

PHS Community Notes - Follow-up on The Picklist (clinician/public)

1. One or two workgroups will be needed to work with Infoway on the different set of terms
2. The group will need to discuss how the patient-friendly or public terms should be published and maintain, who owns those terms. (Roles and responsibility)
3. ACTION:
 1. Bring this topic at the next PHSC meeting.
 2. Recrute volunteers and start the work as per the priority discussion

PHS Community Notes - Follow-up On Who Uses The Antigen And Immunoglobulin Joint Subset

1. Differ this topic after the Subset potential merging has been discussed
2. ACTION:
 1. Put on hold for now

PHS Community Notes - Following Up On Merging Options For The Tradename And Generic/Historical Subsets

1. It was discussed to post all related information on the PHSC Forum and request comments and feedback to be posted on the same Forum
2. If there is a push back, a meeting can be schedule to discuss
3. ACTION:
 1. Linda to post on the PHSC all details (including the pros and cons provided in the June PHSC meeting)
 2. The PHSC to confirm their choice, by providing input on the PHSC Forum before the October meeting
 3. Bring this topic at the next PHSC meeting



Canada Health Infoway

1. Welcome and Introductions (5 min)

New recruits

PHS-Standards SME, full time: Debra Mills

PHS-Standards SME, full time: Myriam Talantikit

Linda Parisien, Canada Health Infoway



Canada Health Infoway

2. New Covid-19 vaccines (10 min)

Naureen Mukhi, Provincial Public Health Information
System – PHSA

Nicolas Gilbert, Public Health Agency Canada - PHAC

New Covid-19 vaccines

- Pfizer BioNTech Comirnaty 30 mcg/ 0.3 mL (DIN: [02541823](#))
- Pfizer BioNTech Comirnaty 10 mcg/ 0.3 mL (DIN: [02541858](#)) – not procured by Canada in Fall 2024
- Pfizer BioNTech Comirnaty 3 mcg/ 0.2 mL (DIN: [02541866](#)) – not procured by Canada in Fall2024
- Moderna Spikevax (DIN: [02541270](#))
- Novavax Nuvaxovid (DIN: [02543656](#))



Canada Health Infoway

3. CIHI Value sets supporting pCHDF (15 min)

Jacqueline Singer, Canadian Institute for Health
Information - CIHI



4. New Requests Since last Meeting and August SNOMED CT CA Edition Release (5 min)

- SNOMED CT CA released on August 31st, 2024
- 9 New Concepts
- 12 New Descriptions
- 4 Description Change

Linda Parisien, Canada Health Infoway

August 31, 2024 SNOMED CT CA Edition Publication

All Canadian specific content available in the [SNOMED International Browser](#):

The screenshot displays the SNOMED CT Browser interface. At the top, the browser address bar shows the URL: `browser.ihtsdotools.org/?perspective=full&conceptId1=385268001&edition=MAIN/SNOMEDCT-CA/2024-08-31&release=&languages=en,fr`. A red box highlights the navigation controls: 'Release: Canadian Edition', 'Version: 2024-08-31', 'Perspective: Full', 'Feedback', and 'About'.

The main interface is divided into several sections:

- Search:** A search bar with the text 'pneu-c' and a search icon. Below it, a message states '11 matches found in 9.568 seconds.'
- Options:** A sidebar on the left containing search filters:
 - Search:** 'Search: Prefix any order', 'Status: Active concepts only', 'Description type: All', 'Language Refsets', and 'Group by concept'.
 - Filter results by Language:** 'english' (5) and 'french' (6).
 - Filter results by Semantic Tag:** 'medicinal product' (6), 'produit médical' (1), and 'real clinical drug' (5).
- Search Results:** A table listing 11 matches for 'pneu-c'. The first few results are:

| Concept ID | Concept Name | Description |
|------------|---|---|
| 385268001 | Pneu-C-7 Pevnar Pfz | Pevnar 16 micrograms per 0.5 milliliter suspension for injection Pfizer Canada Inc. (real clinical drug) |
| 385268002 | Pneu-C-10 SYNFLORIX GSK | SYNFLORIX 16 micrograms per 0.5 milliliter suspension for injection GlaxoSmithKline Inc. (real clinical drug) |
| 385268003 | Pneu-C-13 Pevnar 13 Pfz | Pevnar 13 suspension for injection Pfizer Canada ULC (real clinical drug) |
| 385268004 | Pneu-C-20 PREVNAV 20 Pfz | PREVNAV 20 0.5 milliliter suspension for injection Pfizer Canada ULC (real clinical drug) |
| 385268005 | Pneu-C-15 VAXNEUVANCE Merck | VAXNEUVANCE 0.5 milliliter suspension for injection Merck Canada Inc. (real clinical drug) |
| 385268006 | Pneu-C-15 pneumocoque conjugué non spécifique | Vaccine product containing only Streptococcus pneumoniae capsular polysaccharide antigen conjugated (medicinal product) |
| 385268007 | Pneu-C-7 pneumocoque conjugué 7-valent non spécifique | Vaccine product containing only Streptococcus pneumoniae Danish serotype 4, 6B, 9B, 14, 18C, 19F, and 23F capsular polysaccharide antigens conjugated (medicinal product) |
- Concept Details:** A sidebar on the right showing details for the selected concept 'Oral dose form (dose form)' (SCTID: 385268001). It includes a 'Parents' section with 'Pharmaceutical dose form (dose form)' and a 'Children (39)' section listing various dosage forms like 'Concentrate for conventional release oral and rectal solution (dose form)', 'Conventional release chewable soft capsule (dose form)', etc.

New Requests Since Last PHSC Meeting

FROM MAY 2024 TO AUGUST 2024 – NEW CONCEPT (TRADENAME)

| RFC | Status | Link |
|---|-----------|---------------------------|
| BEYFORTUS 100 milligrams per milliliter for injection Sanofi Pasteur Limited (real clinical drug) | Completed | SCT-27682 |
| BEYFORTUS 50 milligrams per 0.5 milliliter for injection Sanofi Pasteur Limited (real clinical drug) | Completed | SCT-27681 |
| Product containing only nirsevimab (medicinal product) | Completed | SCT-27847 |
| Nirsevimab (substance) | Completed | SCT-27845 |
| VAXCHORA 400000000 to 2000000000 colony forming units per sachet powder for oral suspension Bavarian Nordic AS (real clinical drug) | Completed | SCT-28441 |
| Human poliovirus, vaccine derived (organism) | Completed | SCT-22450 |
| Vaccine product containing only Neisseria meningitidis serogroup C + A conjugated antigen (medicinal product) | Completed | SCT-22047 |
| CAPVAXIVE 0.5 milliliter solution for injection Merck Canada Inc. (real clinical drug) | Completed | SCT-28902 |
| Vaccine product containing only Streptococcus pneumoniae Danish serotype 3, 6A, 6C, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B capsular polysaccharide antigens conjugated (medicinal product) | Completed | SCT-28944 |

New Requests Since Last PHSC Meeting

FROM MAY 2024 TO AUGUST 2024 – NEW DESCRIPTION

| RFC | Status | Link |
|---|-----------|---------------------------|
| FR PT Product containing only palivizumab | Completed | SCT-28241 |
| ADD FR PT NC 58531000087106 Product containing only nirsevimab (medicinal product) | Completed | SCT-27892 |
| ADD FR PT NC 58301000087109 BEYFORTUS 50 milligrams per 0.5 milliliter solution for injection syringe Sanofi Pasteur Limited (real clinical drug) | Completed | SCT-27850 |
| ADD FR PT NC 58291000087105 BEYFORTUS 100 milligrams per 1 milliliter solution for injection syringe Sanofi Pasteur Limited (real clinical drug) | Completed | SCT-27849 |
| ADD FR FSN and PT NC nirsevimab (substance) | Completed | SCT-27848 |
| Add CA EN PT: 1011000221100 Vaccine product containing only live attenuated Vibrio cholerae antigen in oral dose form (medicinal product form) | Completed | SCT-28862 |
| Add EN PT 581000221101 Antigen of live attenuated Vibrio cholerae (substance) | Completed | SCT-28878 |

New Requests Since Last PHSC Meeting

FROM MAY 2024 TO AUGUST 2024 –NEW DESCRIPTION AND CHANGE/RETIRE DESCRIPTION

| RFC | Type | Status | Link |
|--|---------------------------|-----------|---------------------------|
| 60261000087109 - Add translation for VAXCHORA 400000000 to 2000000000 colony forming units per sachet powder for oral suspension Bavarian Nordic AS (real clinical drug) | New Description | Completed | SCT-28866 |
| Add CA FR PT: 1011000221100 Vaccine product containing only live attenuated Vibrio cholerae antigen in oral dose form (medicinal product form) | New Description | Completed | SCT-28863 |
| Add FR translation: 581000221101 Antigen of live attenuated Vibrio cholerae (substance) | New Description | Completed | SCT-28864 |
| Product containing only palivizumab PT | New Description | Completed | SCT-28010 |
| Change Product containing palivizumab FR PT | Change/Retire description | Completed | SCT-28239 |
| Change palivizumab substance FR FSN and PT | Change/Retire description | Completed | SCT-28238 |
| Product containing palivizumab PT | Change/Retire description | Completed | SCT-28008 |
| Palivizumab substance PT | Change/Retire description | Completed | SCT-27846 |



Canada Health Infoway

5. Follow-up On The Picklists (Clinician/Public) Terms (10 min)

Linda Parisien, Canada Health Infoway

Follow-up On The Picklists (Clinician/Public) Terms

Other countries scan :

- **Patient-Friendly or Public Terms:**
 - Implemented in various countries, with documentation from SNOMED International.
- **Clinician Terms:**
 - No examples of countries implementing terms for clinician and/or different contexts or specialties.
 - Multiple contexts are not supported in RF2.
 - Clinician terms are the preferred terms of the national edition.

Recommendations :

1. Infoway is open to support the Patient-Friendly or Public Terms
2. Infoway is open to review the current Preferred Terms for the vaccine concepts if they no longer meet the Canadian PHSC requirements

Follow-up On The Picklists (Clinician/Public) Terms

Important note:

1. The CVC displays for professionals would not be acceptable as SNOMED CT preferred terms in the Canadian edition: Most Terms do not comply to the SNOMED CT editorial policy, some terms are ambiguous
2. For the 2 recommendations, we'd like to recommend a workgroup is created to work with Infoway on the different set of terms
3. The group will need to discuss how the patient-friendly or public terms should be published and maintain, who owns those terms. (Roles and responsibility)



Canada Health Infoway

6. Follow-up On Who Uses The Antigen And Immunoglobulin Joint Subset And For What? (5 min)

Linda Parisien, Canada Health Infoway

Antigen/Immunoglobulin Subsets

- Who uses the joint subset?
- How is the subset used?
- Why is the subset used?
 - Are you using them for forecasting?
 - If so, are you experiencing any challenges?
- If you are not using the joint subset, are you using the individual antigen subset and or the immunoglobulin subset published on the Infoway Terminology Gateway?

Antigen/Immunoglobulin Subsets

Infoway would like to propose to address this as part of the potential subsets changes or potential merger



Canada Health Infoway

7. Following Up On Merging Options For The Tradename And Generic/Historical Subsets (5 min)

Linda Parisien, Canada Health Infoway

Option #1

- **Create 2 new subsets**
 - A new Tradename subset that would combine all active and passive tradename immunizing agents
 - A new Generic subset that would combine all active and passive generic immunizing agents

Option #2

- Merge the current tradenames subsets and the historical subsets (CVC/NVC)
 - The current Tradename subset would combine all active and passive tradename immunizing agents
 - The current Tradename subset scope would need to be adjusted to only contain Tradename immunizing agents
 - The current Historical subset that would combine all active and passive generic immunizing agents
 - The current Historical subset would need to be renamed and scope changed to only contain generic concepts

Option #3

- Keep the four current Tradename and Historical subsets and redefine their scope (and membership)
 - Redefine the scope of each subsets to only have the Tradename in the Tradename subsets and only 'generic' concepts in the Historical subsets
 - VaccineAdministeredTradeNameCode
 - PassiveAdministeredImmunizingAgentCode
 - VaccineHistoricalNameCode
 - PassiveHistoricalImmunizingAgentCode

Merging Options For The Tradename And Generic/Historical Subsets

- **Comments received from the audience in the June meeting:**
 - The Infoway subsets should align with the NVC subsets ==> Option 2?

No comments, feedback or concerns were communicated since the June meeting.

Infoway would like to create a workgroup to work on the details of the proposal, so the changes can be effective in the November 2024 CA Edition release

Prioritization Of Work Items

1. Patient-Friendly Picklist
2. Enhanced Clinician Picklist (Preferred Terms review)
3. Antigen/Immunglobulin content modification
4. Subset mergings
5. Potential new NVC subsets ?



Canada Health Infoway

8. Questions/Wrap up

Next meeting

Thursday, October 3, 2024, 2:00-3:00 pm ET



Canada Health Infoway

Thank you!

Contact Information:

standards@infoway-inforoute.ca

VISIT OUR WEBSITE
infoway-inforoute.ca

VISIT OUR SURVEY WEBSITE
insights.infoway-inforoute.ca

LET'S CONNECT ON LINKEDIN
linkedin.com/company/canada-health-infoway

LET'S CONNECT ON TWITTER
@infoway



Canada Health Infoway

APPENDIX

Merging the Immunization Subsets

(Slides from the June meeting)

VISIT OUR WEBSITE
infoway-inforoute.ca

VISIT OUR SURVEY WEBSITE
insights.infoway-inforoute.ca

LET'S CONNECT ON LINKEDIN
linkedin.com/company/canada-health-infoway

LET'S CONNECT ON TWITTER
[@infoway](https://twitter.com/infoway)

Option #1

- **Create 2 new subsets**
 - A new Tradename subset that would combine all active and passive tradename immunizing agents
 - A new Generic subset that would combine all active and passive generic immunizing agents

- **PROS:**
 - Combined content as CVC had in their solution
 - All tradename immunizing agents would stay in the Tradename subset
 - Decrease the number of subsets

- **CONS:**
 - The current individual subsets and the new ones will need to be maintained concurrently
 - Differentiation of the active from the passive agents difficult (although this may be done by the immunizing agents abbreviation)
 - May cause confusion for implementers as to which subsets need to be implemented

Option #2

- Merge the current tradenames subsets and the historical subsets
 - The current Tradename subset would combine all active and passive tradename immunizing agents
 - The current Tradename subset scope would need to be adjusted to only contain Tradename immunizing agents
 - The current Historical subset that would combine all active and passive generic immunizing agents
 - The current Historical subset would need to be renamed and scope changed to only contain generic concepts
- PROS:
 - Combined content as CVC had in their solution
 - All tradename immunizing agents would stay in the Tradename subset
 - Decrease the number of subsets to maintain (two instead of four)
- CONS:
 - Differentiation of the active from the passive agents difficult (although this may be done by the immunizing agents abbreviation)
 - Change in subsets scope and membership may cause confusion for the implementers

Option #3

- Keep the four current Tradename and Historical subsets and redefine their scope (and membership)
 - Redefine the scope of each subsets to only have the Tradename in the Tradename subsets and only 'generic' concepts in the Historical subsets
 - VaccineAdministeredTradeNameCode
 - PassiveAdministeredImmunizingAgentCode
 - VaccineHistoricalNameCode
 - PassiveHistoricalImmunizingAgentCode

Option #3

- Keep the four Tradename and Historical subsets and redefine their scope (and membership)
 - PROS:
 - No issue to differentiate the active from the passive
 - All tradename immunizing agents would stay in the Tradename subsets
 - No additional maintenance burden for anyone
 - CONS:
 - Not combined as CVC had them in their solution, but NVC can join them in the online tool
 - Change in subsets scope and membership may cause confusion for the implementers

Option #3

- What does this mean:

VaccineHistoricalNameCode

Overview Concepts **Change Logs**

Q Search Reset

| Concept Code | English Display Name | French Display Name | Concept Name |
|----------------|---|--|---|
| 7751000087104 | T-IPV tetanus + inactivated poliomyelitis unspecified | T-VPI tétanos + polio inactivé adulte non spécifié | Vaccine product containing only tetanus + inactivated ... |
| 871719005 | TBE tick-borne encephalitis unspecified | ETT encéphalite transmise par tiques non spécifié | Vaccine product containing only Tick-borne encephalit... |
| 871727001 | Sma smallpox unspecified | Sma variole non spécifié | Vaccine product containing only Vaccinia virus antige... |
| 991000221105 | Chol cholera unspecified | Chol choléra non spécifié | Vaccine product containing only Vibrio cholerae antig... |
| 871717007 | YF yellow fever unspecified | FJ fièvre jaune non spécifié | Vaccine product containing only Yellow fever virus ant... |
| 871718002 | PLAQ plague unspecified | PEST peste non spécifié | Vaccine product containing only Yersinia pestis antige... |
| 45861000087106 | PF Plasmodium falciparum unspecified | PF Plasmodium falciparum non spécifié | Vaccine product containing Plasmodium falciparum a... |
| 7321000087105 | Typh-O Vivotif CS | Typh-O Vivotif CS | Vivotif 10 billion units enteric coated capsule Crucell ... |
| 2421000087105 | Typh-O Vivotif Pax | Typh-O Vivotif Pax | Vivotif 10 billion units enteric coated capsule PaxVax ... |

Showing 127 to 135 of 135 results

Option #3

- New proposal Subsets definition

Vaccineadministeredtradenamecode

- CURRENT:

The scope of this subset is vaccines that are currently licensed for use in Canada and those obtained through special access programs for use in Canada. The subset includes concepts represented by the trade name (brand name) of the vaccine administered to the client. This content is intended to be used when populating a record at the point of immunization.

- PROPOSE CHANGE:

The subset includes concepts represented by the trade name (brand name) of the vaccine administered to the client. The scope of this subset is **all** vaccines that **have been ~~are currently~~** licensed for use in Canada, **and** those obtained through special access programs for use in Canada, **and those that were never licensed in Canada (i.e., administered in other countries).**

Option #3

- New proposal Subsets definition

Vaccinehistoricalnamecode

CURRENT:

The scope of this subset is vaccines that are currently licensed for use in Canada (generic description, i.e. no trade name), those obtained through special access programs (generic description), and vaccines that have been discontinued and/or never licensed in Canada (with trade name). This content is intended to be used when populating an immunization history when the client and /or provider does not have the detail of the trade name (brand name) of the vaccine administered OR the product has been discontinued and/or never licensed in Canada. This subset will include concepts represented by a generic description for a vaccine that was previously administered to the client as may be expressed by the client or provider for an immunization history and concepts represented by the trade name for products that have been discontinued and/or never licensed in Canada.

PROPOSE CHANGE:

The scope of this subset is **generic** vaccines that **have been are currently** licensed for use in Canada ~~(generic description, i.e. no trade name)~~, those obtained through special access programs ~~(generic description)~~, and for vaccines that ~~have been discontinued and/or were~~ never licensed in Canada. ~~(with trade name)~~. This content is intended to be used when populating an immunization history when the client and /or provider does not have the detail of the trade name (brand name) of the vaccine administered **or OR** the product has ~~been discontinued and/or~~ never **been** licensed in Canada. This subset will include concepts represented by a generic description for a vaccine that was previously administered to the client as may be expressed by the client or provider for an immunization history and concepts represented by the trade name for products. ~~that have been discontinued and/or never licensed in Canada.~~

Option #3

- New proposal Subsets definition

PassiveAdministeredImmunizingAgentCode

CURRENT:

The scope of this subset is passive immunizing agents that are currently licensed for use in Canada and those obtained through special access programs. The subset includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the client. Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent. This content is intended to be used when populating a record at the point of administration.

PROPOSE CHANGE:

The subset includes concepts represented by the trade name (brand name) of the passive immunizing agent (immune globulin or antitoxin) that was administered to the client. The scope of this subset is **all** passive immunizing agents that **have been are currently** licensed for use in Canada, **and** those obtained through special access programs for use in Canada, **and those that were never licensed in Canada (i.e., administered in other countries)**. Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent.

Option #3

- New proposal Subsets definition

PassiveHistoricalImmunizingAgentCode

CURRENT:

The scope of this subset is passive immunizing agents used in Canada (generically described, i.e. without trade name), those obtained through special access programs (generically described), and agents that have been discontinued and/or never licensed in Canada (with trade name). This content is intended to be used when populating an immunization history when the client and/or provider does not have the detail of the trade name of the agent administered OR the product has been discontinued and/or never licensed in Canada. Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent. This subset will include concepts represented by a generic description for an agent that was previously administered to the client as may be expressed by the client or provider for an immunization history and concepts represented by the trade name for products that have been discontinued and/or never licensed in Canada.

PROPOSE CHANGE:

The scope of this subset is **generic** passive immunizing agents used in Canada (generically described, i.e. without trade name), those obtained through special access programs (generically described), and **passive** agents that ~~have been discontinued and/or were never licensed in Canada. (with trade name).~~ This content is intended to be used when populating an immunization history when the client and/or provider does not have the detail of the trade name of the agent administered **or** ~~OR~~ the product has **been discontinued and/or never been** licensed in Canada. Passive immunizing agents are used to facilitate protection against vaccine preventable infections, when vaccines are not available or are contraindicated or when vaccines have not been used before exposure to the infective agent. This subset will include concepts represented by a generic description for ~~an~~ **a passive** agent that was previously administered to the client as may be expressed by the client or provider for an immunization history and concepts represented by the trade name for products. ~~that have been discontinued and/or never licensed in Canada.~~

Merging Options For The Tradename And Generic/Historical Subsets

- Comments received from the audience:
 - The Infoway subsets should align with the NVC subsets
 - Option #2 was preferred by one jurisdiction

REQUEST FOR ACTION FROM THE PHSC:

Please provide feedback and comments on this topic on the PHSC Forum at any moment between now and September, so the changes can be effective in the November 2024 CA Edition release